Skip to content

Compare medicines

Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.

Attribute
In shortOral immunomodulatory drug for myeloma; strict pregnancy-prevention programme.Proteasome inhibitor injection for multiple myeloma.
Body systemCancerCancer
Drug classMyeloma agentsMyeloma agents
SupplyPrescription onlyWHO essential medicinePrescription onlyWHO essential medicine
Main usesMultiple myeloma, Myelodysplastic syndromes with 5q deletion, Some lymphomasMultiple myeloma, Mantle cell lymphoma
How it worksBoosts immune attack on myeloma cells.Disrupts protein recycling in myeloma cells.
Starts workingDepends on the cancer and regimenDepends on the cancer and regimen
Half-lifeAbout 3 hours40–193 hours
Typical adult doseDosed by your cancer team according to the treatment protocol.Dosed by your cancer team according to the treatment protocol.
FormsCapsuleSubcutaneous injection, IV injection
Common side effectsTiredness, Low blood counts, Diarrhoea, Constipation, Muscle cramps, RashTingling and numbness, Low platelets, Nausea, Diarrhoea, Tiredness
Serious side effectsBlood clots, Severe neutropenia, Birth defects, Second cancersPainful nerve damage, Low blood pressure, Shingles reactivation
Don't take ifPregnancy; Women able to become pregnant without contraception; Severe kidney impairment without dose reductionPregnancy; Intrathecal administration (fatal)
AlcoholBest to limit. Alcohol can add to tiredness.Best to limit. Alcohol can worsen dizziness.
PregnancyUsually avoidedCauses severe birth defects. A pregnancy-prevention programme applies.Usually avoidedAvoid.
BreastfeedingUsually avoidedAvoid.Usually avoidedAvoid.
In use since——
Brand namesUnited States: RevlimidUnited Kingdom: RevlimidIndia: Revlimid, Lenalid, Lenalidomide (generic)United States: VelcadeUnited Kingdom: VelcadeIndia: Velcade, Bortenat, Bortezomib (generic)
Legal statusUnited States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM)India: Schedule HUnited States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM), hospital useIndia: Schedule H
ATC codeL04AX04L01XG01

Taken together

  • ModerateLenalidomide + Bortezomib: Added bone marrow suppression

    Both can lower white cells, red cells or platelets; together the risk of infection and bleeding rises.

Open in the interaction checker